| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yosef Ron, Hedva Lerman, Einat Even-Sapi. [METABOLIC AND DOPAMINERGIC BRAIN FUNCTIONAL IMAGING IN DEMENTIA WITH LEWY BODIES]. Harefuah. vol 160. issue 7. 2021-07-16. PMID:34263568. |
cortical metabolism was obtained by pet with labeled glucose (fdg) and the dopaminergic activity by labeled precursor (f-dopa) of the neurotransmitter dopamine. |
2021-07-16 |
2023-08-13 |
Not clear |
| Nageen Mubashir, Rida Fatima, Sadaf Naee. Identification of Novel Phyto-chemicals from Ocimum basilicum for the Treatment of Parkinson's Disease using In Silico Approach. Current computer-aided drug design. vol 16. issue 4. 2021-07-15. PMID:32883197. |
parkinson's disease is characterized by decreased level of dopaminergic neurotransmitters and this decrease is due to the degradation of dopamine by protein monoamine oxidase b (mao-b). |
2021-07-15 |
2023-08-13 |
Not clear |
| Sergi Ferré, Xavier Guitart, César Quiroz, William Rea, Celia García-Malo, Diego Garcia-Borreguero, Richard P Allen, Christopher J Earle. Akathisia and Restless Legs Syndrome: Solving the Dopaminergic Paradox. Sleep medicine clinics. vol 16. issue 2. 2021-07-13. PMID:33985651. |
this article proposes that it involves an increased presynaptic dopaminergic transmission in the ventral striatum and concomitant strong activation of postsynaptic dopamine d |
2021-07-13 |
2023-08-13 |
Not clear |
| Antonio Verduzco-Mendoza, Paul Carrillo-Mora, Alberto Avila-Luna, Arturo Gálvez-Rosas, Adriana Olmos-Hernández, Daniel Mota-Rojas, Antonio Bueno-Nav. Role of the Dopaminergic System in the Striatum and Its Association With Functional Recovery or Rehabilitation After Brain Injury. Frontiers in neuroscience. vol 15. 2021-07-13. PMID:34248494. |
previous studies have shown that dopamine (da) neurotransmission is disrupted following moderate to severe tbi and have reported beneficial effects of drugs that affect the dopaminergic system. |
2021-07-13 |
2023-08-13 |
Not clear |
| Yuan-Bing Huang, Ze-Gang Ma, Chao Zheng, Xiao-Kuang K Ma, Devin H Taylor, Ming Gao, Ronald J Lukas, Jie W. Levo-tetrahydropalmatine inhibits α4β2 nicotinic receptor response to nicotine in cultured SH-EP1 cells. Acta pharmacologica Sinica. 2021-07-13. PMID:34253876. |
l-tetrahydropalmatine (l-thp) is an active ingredient of the chinese medicinal herb corydalis ambigua that possesses rich neuropharmacological actions on dopamine (da) receptors in the mesocorticolimbic dopaminergic reward pathway. |
2021-07-13 |
2023-08-13 |
human |
| Bruk Getachew, Antonei B Csoka, Amna Bhatti, Robert L Copeland, Yousef Tizab. Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson's Disease. Neurotoxicity research. vol 38. issue 3. 2021-07-09. PMID:32572814. |
sals, an endogenous product of aldehyde and dopamine condensation, may be selectively toxic to dopaminergic neurons. |
2021-07-09 |
2023-08-13 |
human |
| Giacomo Grassi, Giovanni Albani, Federica Terenzi, Lorenzo Razzolini, Silvia Rama. New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 42. issue 7. 2021-07-09. PMID:33852081. |
these behaviors have been consistently linked to the use of dopaminergic medications used to treat pd motor symptoms (dopamine agonists, levodopa, and other agents) and less consistently to neuromodulation techniques such as deep brain stimulation (dbs). |
2021-07-09 |
2023-08-13 |
Not clear |
| Atsushi Takeda, Masahiko Tomiyama, Ritsuko Hanajim. [The Relationship Between Pathophysiology and Neurotransmitters in Parkinson's Disease]. Brain and nerve = Shinkei kenkyu no shinpo. vol 73. issue 7. 2021-07-09. PMID:34234041. |
the major motor symptoms of pd are mainly caused by dopamine (da) deficiency due to the loss of dopaminergic neurons in the substantia nigra. |
2021-07-09 |
2023-08-13 |
Not clear |
| Yiqiu Liu, Junyu Deng, Ye Liu, Wei Li, Xuqiang Ni. FGF, Mechanism of Action, Role in Parkinson's Disease, and Therapeutics. Frontiers in pharmacology. vol 12. 2021-07-09. PMID:34234672. |
the death or dysfunction of dopaminergic neurons in the dense part of the substantia nigra leads to dopamine deficiency in the basal ganglia and motor dysfunction. |
2021-07-09 |
2023-08-13 |
Not clear |
| Owen Y Chao, Salil S Pathak, Hao Zhang, Nathan Dunaway, Jay-Shake Li, Claudia Mattern, Susanne Nikolaus, Joseph P Huston, Yi-Mei Yan. Altered dopaminergic pathways and therapeutic effects of intranasal dopamine in two distinct mouse models of autism. Molecular brain. vol 13. issue 1. 2021-07-08. PMID:32778145. |
altered dopaminergic pathways and therapeutic effects of intranasal dopamine in two distinct mouse models of autism. |
2021-07-08 |
2023-08-13 |
mouse |
| Zulfiye Gul, Gozde Duyu, Burcin Altinbas, R Levent Buyukuysa. K channel blockage with 3,4-diaminopyridine potentiates the effect of L-DOPA on dopamine release in striatal slices prepared from 6-OHDA pre-treated rats. Experimental brain research. vol 238. issue 11. 2021-07-07. PMID:32870323. |
it has been shown that 3,4-diaminopyridine (3,4-dap), a k channel blocker, increased dopamine release from striatal slices by increasing neuronal firing in striatal dopaminergic terminals. |
2021-07-07 |
2023-08-13 |
rat |
| Zulfiye Gul, Gozde Duyu, Burcin Altinbas, R Levent Buyukuysa. K channel blockage with 3,4-diaminopyridine potentiates the effect of L-DOPA on dopamine release in striatal slices prepared from 6-OHDA pre-treated rats. Experimental brain research. vol 238. issue 11. 2021-07-07. PMID:32870323. |
the current study investigates whether 3,4-dap may enhance l-dopa-induced dopamine (da) release from striatal slices by increasing neuronal firing in striatal dopaminergic terminals. |
2021-07-07 |
2023-08-13 |
rat |
| Tanvi Pingale, Girdhari Lal Gupt. Classic and evolving animal models in Parkinson's disease. Pharmacology, biochemistry, and behavior. vol 199. 2021-07-07. PMID:33091373. |
pd is characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (snpc) and deficiency of dopamine in the striatal region. |
2021-07-07 |
2023-08-13 |
Not clear |
| Shawn Zheng Kai Tan, Yasin Temel, Ariel Yovela Chan, Andrea Tsz Ching Mok, Jose Angelo Udal Perucho, Arjan Blokland, Luca Aquili, Wei Ling Lim, Lee Wei Li. Serotonergic treatment normalizes midbrain dopaminergic neuron increase after periaqueductal gray stimulation. Brain structure & function. vol 225. issue 7. 2021-07-06. PMID:32594260. |
we then attempted to unravel some of the interactions with dopamine signalling using tyrosine hydroxylase (th) immunohistochemistry to probe the effects on dopaminergic neurons. |
2021-07-06 |
2023-08-13 |
rat |
| Louise Pape, Koen van Lith, Dick Veltman, Moran Cohn, Reshmi Marhe, Wim van den Brink, Theo Doreleijers, Arne Popm. Effect of Methylphenidate on Resting-State Connectivity in Adolescents With a Disruptive Behavior Disorder: A Double-Blind Randomized Placebo-Controlled fMRI Study. Frontiers in psychiatry. vol 12. 2021-07-06. PMID:34220576. |
mph is a dopamine and norepinephrine reuptake inhibitor and thus it is likely to affect dopaminergic mesocorticolimbic pathways. |
2021-07-06 |
2023-08-13 |
human |
| Aliasghar Karimi, Mitra Elmi, Zahra Shiri, Hossein Baharvan. Therapeutic potential of pluripotent stem cell-derived dopaminergic progenitors in Parkinson's disease: a systematic review protocol. Systematic reviews. vol 10. issue 1. 2021-07-05. PMID:34172098. |
this disease is associated with a loss of dopamine content within the putamen, which stems from the degeneration of dopaminergic (da) neurons in the substantia nigra pars compacta (snc). |
2021-07-05 |
2023-08-13 |
human |
| Shaili Aggarwal, Mary Hongying Cheng, Joseph M Salvino, Ivet Bahar, Ole Valente Mortense. Functional Characterization of the Dopaminergic Psychostimulant Sydnocarb as an Allosteric Modulator of the Human Dopamine Transporter. Biomedicines. vol 9. issue 6. 2021-07-05. PMID:34199621. |
functional characterization of the dopaminergic psychostimulant sydnocarb as an allosteric modulator of the human dopamine transporter. |
2021-07-05 |
2023-08-13 |
human |
| Steven Vetel, Laura Foucault-Fruchard, Claire Tronel, Frédéric Buron, Jackie Vergote, Sylvie Bodard, Sylvain Routier, Sophie Sérrière, Sylvie Chalo. Neuroprotective and anti-inflammatory effects of a therapy combining agonists of nicotinic α7 and σ1 receptors in a rat model of Parkinson's disease. Neural regeneration research. vol 16. issue 6. 2021-07-03. PMID:33269756. |
although no effect was noticed in the amphetamine-induced rotation test, our data has shown that the pha/pre treatment induced partial protection of the dopaminergic neurons (15-20%), assessed by the dopamine transporter density in the striatum and immunoreactive tyrosine hydroxylase in the substantia nigra. |
2021-07-03 |
2023-08-13 |
rat |
| Zhuang-Yao D Wei, Ashok K Shett. Treating Parkinson's disease by astrocyte reprogramming: Progress and challenges. Science advances. vol 7. issue 26. 2021-07-02. PMID:34162545. |
such in vivo astrocyte reprogramming in the mouse model of pd has successfully added new dopaminergic neurons to the substantia nigra and increased dopamine levels associated with axonal projections into the striatum. |
2021-07-02 |
2023-08-13 |
mouse |
| Khadga Raj, G D Gupta, Shamsher Sing. l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson's disease. Drug and chemical toxicology. 2021-07-02. PMID:34210222. |
parkinson's disease (pd) is the second most prevalent progressive neurodegenerative disease, characterized by loss of dopaminergic neurons in substantia nigra, with deficiency of dopamine in the striatum. |
2021-07-02 |
2023-08-13 |
rat |